Payment overview · 2025
General Payments
$221.11
11 reported records · 8 companies
Healthcare provider profile · identity verified
Ginaida Cirilo, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · ROCKWALL, TX · NPI 1952539678
Verified facts
What the public records show
CMS Open Payments records show Ginaida Cirilo, M.D. received $221.11 in general payments during 2025 across 11 reported records.
ABBVIE INC. accounted for 23.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Farxiga by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 92 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $52.47 | 23.7% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $38.56 | 17.4% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $32.35 | 14.6% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $24.23 | 11.0% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $21.65 | 9.8% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $21.57 | 9.8% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $15.95 | 7.2% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $14.33 | 6.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $221.11 | 11 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $38.56 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $29.35 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $24.23 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $23.12 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $23.12 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $21.65 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $21.57 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $16.25 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $16.10 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $15.95 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $15.95 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $14.33 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 92 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
48 | 18 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
92 | 23 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
43 | 17 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
18 | 18 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 479 | 150 |
| Atorvastatin Calcium | Atorvastatin Calcium | 412 | 139 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 341 | 119 |
| Losartan Potassium | Losartan Potassium | 284 | 91 |
| Amlodipine Besylate | Amlodipine Besylate | 268 | 84 |
| Gabapentin | Gabapentin | 245 | 108 |
| Omeprazole | Omeprazole | 219 | 73 |
| Lisinopril | Lisinopril | 218 | 74 |
| Metformin Hcl | Metformin Hcl | 200 | 71 |
| Montelukast Sodium | Montelukast Sodium | 200 | 67 |
| Pantoprazole Sodium | Pantoprazole Sodium | 193 | 73 |
| Fluticasone Propionate | Fluticasone Propionate | 189 | 107 |
| Trazodone Hcl | Trazodone Hcl | 163 | 58 |
| Metoprolol Succinate | Metoprolol Succinate | 148 | 41 |
| Hydrochlorothiazide | Hydrochlorothiazide | 142 | 54 |
| Escitalopram Oxalate | Escitalopram Oxalate | 141 | 43 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 138 | 54 |
| Prednisone | Prednisone | 136 | 107 |
| Famotidine | Famotidine | 130 | 46 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 128 | 31 |
| Donepezil Hcl | Donepezil Hcl | 126 | 40 |
| Alprazolam | Alprazolam | 117 | 41 |
| Alendronate Sodium | Alendronate Sodium | 111 | 40 |
| Furosemide | Furosemide | 109 | 43 |
| Tamsulosin Hcl | Tamsulosin Hcl | 109 | 41 |
| Carvedilol | Carvedilol | 108 | 36 |
| Sertraline Hcl | Sertraline Hcl | 105 | 33 |
| Meloxicam | Meloxicam | 100 | 41 |
| Tramadol Hcl | Tramadol Hcl | 96 | 32 |
| Citalopram Hbr | Citalopram Hydrobromide | 95 | 33 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 93 | 33 |
| Ozempic | Semaglutide | 92 | 23 |
| Duloxetine Hcl | Duloxetine Hcl | 85 | 28 |
| Ezetimibe | Ezetimibe | 83 | 29 |
| Tizanidine Hcl | Tizanidine Hcl | 83 | 38 |
| Pravastatin Sodium | Pravastatin Sodium | 81 | 26 |
| Allopurinol | Allopurinol | 80 | 27 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 79 | 25 |
| Zolpidem Tartrate | Zolpidem Tartrate | 79 | 24 |
| Simvastatin | Simvastatin | 78 | 26 |
| Glipizide | Glipizide | 77 | 28 |
| Bupropion Xl | Bupropion Hcl | 71 | 18 |
| Ipratropium Bromide | Ipratropium Bromide | 69 | 24 |
| Estradiol | Estradiol | 66 | 25 |
| Metoprolol Tartrate | Metoprolol Tartrate | 65 | 23 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 64 | 53 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 64 | 23 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 64 | 50 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 64 | 38 |
| Fluconazole | Fluconazole | 62 | 36 |
| Jardiance | Empagliflozin | 60 | 19 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 59 | 51 |
| Ropinirole Hcl | Ropinirole Hcl | 57 | 15 |
| Clopidogrel | Clopidogrel Bisulfate | 55 | 21 |
| Mounjaro | Tirzepatide | 50 | 14 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 49 | 44 |
| Clonazepam | Clonazepam | 48 | 16 |
| Memantine Hcl | Memantine Hcl | 48 | 18 |
| Synthroid | Levothyroxine Sodium | 48 | 18 |
| Atenolol | Atenolol | 47 | 16 |
| Buspirone Hcl | Buspirone Hcl | 47 | 19 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 46 | 16 |
| Potassium Chloride | Potassium Chloride | 45 | 21 |
| Eliquis | Apixaban | 43 | 17 |
| Nifedipine Er | Nifedipine | 43 | 13 |
| Lorazepam | Lorazepam | 42 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 39 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 37 | suppressed |
| Telmisartan | Telmisartan | 37 | suppressed |
| Azithromycin | Azithromycin | 36 | 34 |
| Meclizine Hcl | Meclizine Hcl | 36 | 19 |
| Ondansetron Odt | Ondansetron | 36 | 26 |
| Valacyclovir | Valacyclovir Hcl | 36 | 23 |
| Benazepril Hcl | Benazepril Hcl | 35 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 35 | 14 |
| Metformin Hcl Er | Metformin Hcl | 35 | 16 |
| Hydralazine Hcl | Hydralazine Hcl | 34 | 12 |
| Celecoxib | Celecoxib | 32 | 12 |
| Spironolactone | Spironolactone | 32 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 31 | 16 |
| Levofloxacin | Levofloxacin | 31 | 27 |
| Diclofenac Sodium | Diclofenac Sodium | 29 | suppressed |
| Ketoconazole | Ketoconazole | 29 | 16 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 28 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 28 | suppressed |
| Finasteride | Finasteride | 28 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 28 | suppressed |
| Trulicity | Dulaglutide | 28 | suppressed |
| Xarelto | Rivaroxaban | 28 | suppressed |
| Prolia | Denosumab | 27 | 19 |
| Amitriptyline Hcl | Amitriptyline Hcl | 26 | suppressed |
| Anastrozole | Anastrozole | 26 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 26 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 26 | 12 |
| Glimepiride | Glimepiride | 25 | 14 |
| Glyxambi | Empagliflozin/Linagliptin | 23 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Pregabalin | Pregabalin | 23 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 22 | suppressed |
| Myrbetriq | Mirabegron | 22 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 22 | 20 |
| Irbesartan | Irbesartan | 21 | suppressed |
| Nystatin | Nystatin | 21 | 18 |
| Quetiapine Fumarate | Quetiapine Fumarate | 21 | suppressed |
| Repatha Sureclick | Evolocumab | 21 | suppressed |
| Vascepa | Icosapent Ethyl | 21 | suppressed |
| Cephalexin | Cephalexin | 20 | 15 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 20 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 20 | suppressed |
| Repatha Syringe | Evolocumab | 19 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 19 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 18 | 18 |
| Diazepam | Diazepam | 17 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 17 | suppressed |
| Temazepam | Temazepam | 17 | suppressed |
| Metronidazole | Metronidazole | 16 | 15 |
| Mupirocin | Mupirocin | 16 | 14 |
| Cefdinir | Cefdinir | 15 | 15 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 14 | suppressed |
| Chlorthalidone | Chlorthalidone | 14 | suppressed |
| Glipizide Er | Glipizide | 14 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Verapamil Er | Verapamil Hcl | 14 | suppressed |
| Amoxicillin | Amoxicillin | 13 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 13 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 13 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 13 | suppressed |
| Modafinil | Modafinil | 13 | suppressed |
| Ramipril | Ramipril | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 13 | suppressed |
| Baclofen | Baclofen | 12 | suppressed |
| Bumetanide | Bumetanide | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Methimazole | Methimazole | 12 | suppressed |
| Primidone | Primidone | 12 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 12 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 11 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 11 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 11 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 11 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 11 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 11 | suppressed |
| Progesterone | Progesterone, Micronized | 11 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 11 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $221.11 · 11 records | ABBVIE INC. | AIRSUPRA, Cologuard Collection Kit, Dexcom G6 Transmitter, FREESTYLE LIBRE 3, LINZESS, NURTEC ODT, Ozempic, QULIPTA, UBRELVY, Wegovy, ZAVZPRET, ZORYVE | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error